Cuardaigh malartuithe:
"eso opens" » "best opens" (Fairsingigh an Cuardach), "era opens" (Fairsingigh an Cuardach), "o opens" (Fairsingigh an Cuardach), "edo opens" (Fairsingigh an Cuardach), "eao opens" (Fairsingigh an Cuardach), "eo opens" (Fairsingigh an Cuardach)
"eo open" » "neo open" (Fairsingigh an Cuardach), "do open" (Fairsingigh an Cuardach), "ao open" (Fairsingigh an Cuardach)
"so open" » "do open" (Fairsingigh an Cuardach), "ao open" (Fairsingigh an Cuardach), "o open" (Fairsingigh an Cuardach)
"esmo open" » "esto open" (Fairsingigh an Cuardach), "ecmo open" (Fairsingigh an Cuardach)
A mostrar 1 - 20 resultados de 865 para a pesquisa '(((((("eo open") OR ("eso opens"))) OR ("esmo open"))) OR ("so open"))', am an iarratais: 0.77seg Refinar resultados
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Plasmodesmata. A Not So Open-and-Shut Case
Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]
Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]
Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]

Uirlisí Cuardaigh: Faigh Fotha RSS — Seol an Cuardach seo mar Ríomhphost — Sábháil an Cuardach